National Center for HIV, Viral Hepatitis, STD, and TB Prevention Division of Viral Hepatitis




CDC Recommendations for Hepatitis B Screening and Testing

Erin Conners, PhD Division of Viral Hepatitis


Hepatitis B Foundation Webinar March 27, 2023 People with chronic hepatitis B virus infection are at increased risk for liver cancer and cirrhosis and are 70%–85% more likely to die prematurely than the general population.

Bixler. Clin Infect Dis. 2019;68(6); Montuclard. J Hepatol. 2015;62(6); Beasley Lancet. 1981;2(8256); McMahon. Arch Intern Med. 1990;150(5)



<section-header><section-header><text>

Roberts H, et al. Hepatology. 2021; Wong RJ, et al. Hepatology. 2021



34% are aware of their infection

Roberts H, et al. Hepatology. 2021

Limitations of current risk-based testing approach




Over 2/3 of reported acute cases were either missing risk data or reported no identified risk

https://www.cdc.gov/hepatitis/statistics/2020surveillance/index.htm

NEW: Screening is recommended for all adults aged >18 years at least once in a lifetime



UNCHANGED: Screening is recommended for all pregnant persons during each pregnancy, preferably in the first trimester, regardless of vaccination status or history of testing



Interpretation of hepatitis B serologic test results

Clinical State	HBsAg	Anti-HBs	Total Anti- HBc	Action
Acute infection	Positive	Negative	Positive (IgM positive)	Link to hepatitis B care
Chronic infection	Positive	Negative	Positive (IgM negative)	Link to hepatitis B care
Resolved infection	Negative	Positive	Positive	Counsel
Immune from vaccination	Negative	Positive	Negative	Reassure if history of HepB vaccine series completion
Susceptible, never infected	Negative	Negative	Negative	Offer HepB vaccine if no history of HepB vaccine series completion
Isolated core antibody positive	Negative	Negative	Positive	Consult with specialist

Testing recommendations

- History of risk for HBV infection (all ages)
 - susceptible during the period of risk

Periodic testing for susceptible persons (all ages)

ongoing risk, while risk persists

NEW: Anyone who requests hepatitis B testing should receive it, regardless of disclosure of risk.

Rationale for Universal Screening

- HBV infection has substantial morbidity and mortality
- Chronic infection can be detected before the development of severe liver disease using reliable and inexpensive screening tests
- ✓ Treatment for chronic HBV infection can reduce morbidity and mortality
- ✓ Reduce risk of transmission
- ✓ Cost-effective
- ✓ Screening can identify people who are at risk for reactivation
- ✓ Screening might identify people who would benefit from vaccination

2022 ACIP Recommendations Adult HepB Vaccination



The following groups should receive hepatitis B vaccines:

- Adults aged 19 59 years
- Adults aged <u>></u> 60 years with risk factors for hepatitis B

The following groups may receive hepatitis B vaccines:

 Adults aged <u>></u> 60 years without known risk factors for hepatitis B




- Collect blood
- Offer vaccine per ACIP
- No need to wait for results
- Screening should not be a barrier

What if the provider can't offer screening at the time of Hep B vaccination?

- Screening should not be a barrier to HepB vaccination
- One-time screening with a triple panel should still be offered during future visits, where blood draw is available
 - cost-effective
- Transient HBsAg positivity can occur within 30 days after vaccination

Schillie S (2018) MMWR;67(No. RR-1); Campioli CC (2021). Mayo Clinic Proceedings: Innovations, Quality & Outcomes; 5(3), 542-547.


Incorporating hepatitis B screening into a clinic workflow Nonpregnant adults >18 years without a known history of HBV infection




The following people have an increased risk for HBV infection and are recommended for periodic testing:

- infants born to hepatitis B surface antigen (HBsAg)-positive pregnant people
- people born in regions with hepatitis B prevalence >2%
- U.S.-born people not vaccinated as infants whose parents were born in regions with hepatitis B prevalence >8%
- people with current or past IDU
- people currently or formerly incarcerated in a jail, prison, or other detention setting [<u>New</u> <u>recommendation</u>]
- people with HIV infection
- people with current or past hepatitis C virus infection [New recommendation]
- men who have sex with men
- people with current or past sexually transmitted infections (STIs) or multiple sex partners [<u>New</u> <u>recommendation</u>]
- current or former household contacts of people with known HBV infection
- needle-sharing or sexual contacts of people with known HBV infection
- persons on maintenance dialysis, including in-center or home hemodialysis and peritoneal dialysis, or who are predialysis
- people with elevated alanine aminotransferase (ALT) or aspartate aminotransferase (AST) levels of unknown origin

Incorporating hepatitis B testing into a clinic workflow Nonpregnant adults <u>></u>18 years without a known history of HBV infection



Incorporating hepatitis B screening and testing into a clinic workflow Children and adolescents 1–17 years without a known history of hepatitis B virus infection



Clinical Considerations

Frequency of periodic testing a shared decision

- individual risk factors, immune status

Multiple sex partners

- insufficient evidence
- number of partners, type of sex, timing of last test

Clinical benefits of screening <u>>80</u> years of age

Hypothetical Clinical Scenario

Charlie, 42yo

- History of injection drug use, doesn't currently use drugs
- Doesn't remember if vaccinated
- No evidence of prior screening

Had an Previously Offer vaccine activity, No screened No/Unk exposure, or for HBV condition infection? associated Offer testing and Yes with increased Yes vaccine risk since the last screening? Completed hepatitis B Offer screening No/Unknown vaccine series? Previously Had an screened No action activity, Yes No for HBV exposure, or infection? condition Offer testing if the Yes exposure occurred associated with increased before vaccination Yes risk since the (while susceptible) last and after the screening? previous HBV test(s)

No/Unknown

Offer screening and

vaccine

Visit 1

Charlie, 42yo

- History of IDU, doesn't currently use drugs
- Doesn't remember if vaccinated
- No evidence of prior screening



Visit 1

- Draw blood for triple panel prior to vaccination
- Charlie declined vaccination

Charlie, 42yo

- History of IDU, doesn't currently use drugs
- Doesn't remember if vaccinated
- No evidence of prior screening



Visit 1: summary

- Results:
 - HBsAg negative
 - Total Anti-HBc negative
 - Anti-HBs negative
- Interpretation: No history of infection, susceptible

Visit 2 (1-year later)


Charlie, 43yo

- History of IDU, didn't use drugs in past year
- Reported 4 sexual partners in past year

Visit 2 (1-year later)



- History of IDU, didn't use drugs in past year
- Reported 4 sexual partners in past year



Visit 2: summary

Charlie, 43yo

- History of IDU, didn't use drugs in past year
- Reported 4 sexual partners in past year



Discuss sexual risk

- decided to test because inconsistent condom usage
- clinical judgement

Because previously screened, chose AASLD testing strategy

Total anti-HBc, followed by HBsAg and anti-HBs if positive

Charlie, 43yo

- History of IDU, didn't use drugs in past year
- Reported 4 sexual partners in past year




Visit 2: summary

- Results:
 - Total anti-HBc negative
- Interpretation: No history of infection, susceptible
- Continue to consider testing at future visits, depending on risk factors
- Continue to recommend HepB vaccine at future visits

Visit 1

Mei, 13

- Immigrated from China 5 years ago
- No hepB vaccine as infant
- Completed hepB series at 8 years old





Visit 1

Mei, 13

- Immigrated from China 5 years ago
- No hepB vaccine as infant
- Completed hepB series at 8 years old

Order triple panel for screening

Potential for exposure as infant or young child



Mei, 13

- Immigrated from China 5 years ago
- No hepB vaccine as infant
- Completed hepB series at 8 years old



Visit 1

Results:

- HBsAg negative
- Anti-HBc negative
- Anti-HBs negative
- Interpretation: No history of infection.
 Has documented, complete series, no need for additional vaccine.
 - anti-HBs may wane, but still protected

Other Resources

Hepatitis B Online – University of Washington

- <u>https://www.hepatitisb.uw.edu/</u>
- Hepatitis B Management: Guidance for the Primary Care Provider

Web MD

- provider self-assessment on current guidance for prevention and management of viral hepatitis
- Hepatitis B Foundation
 - <u>https://www.hepb.org/</u>
- Immunize.org
 - <u>https://www.immunize.org/askexperts/experts_hepb.asp</u>

Acknowledgements

Guideline workgroup and steering committee

- Noele Nelson
- Lakshmi Panagiotakopoulos
- Jessica Brown
- Liesl Hagan
- Aaron Harris
- Megan Hofmeister
- Karina Rapposelli
- Amy Sandul
- Philip Spradling
- Carolyn Wester

Prevention Policy Modeling Lab

- Mehlika Toy
- David Hutton
- Joshua Salomon
- Samuel So

HepB Vaccine Guidance

Mark Weng

All adults should know their HBV status and be protected from infection

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

